# Immunome Inc.: financial statements, quarterly

IMNM · Nasdaq · CIK 1472012 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imnm.md) · [Financials](/companies/imnm/financials.md) · [Filings](/companies/imnm/filings.md) · [Insiders](/companies/imnm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/imnm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.6](/filings/0001558370-24-015524.md) | [3.8 d](/filings/0001558370-25-003302.md) | [1.0](/filings/0001558370-25-007382.md) | [2.4](/filings/0000950170-25-104035.md) | [2.9](/filings/0001193125-25-269603.md) | [2.7 d](/filings/0001193125-26-088172.md) | [2.9](/filings/0001193125-26-219425.md) | [4.0](/filings/0001193125-26-344636.md) | [0.0](/filings/0001193125-25-269603.md) | [0.0 d](/filings/0001193125-26-088172.md) | [0.0](/filings/0001193125-26-219425.md) | [0.0](/filings/0001193125-26-344636.md) |
| Research and development | $m | [3.8](/filings/0001558370-24-015524.md) | [9.6 d](/filings/0001558370-25-003302.md) | [15.4](/filings/0001558370-25-007382.md) | [29.1](/filings/0000950170-25-104035.md) | [37.2](/filings/0001193125-25-269603.md) | [47.9 d](/filings/0001193125-26-088172.md) | [36.9](/filings/0001193125-26-219425.md) | [40.5](/filings/0001193125-26-344636.md) | [49.2](/filings/0001193125-25-269603.md) | [50.8 d](/filings/0001193125-26-088172.md) | [46.4](/filings/0001193125-26-219425.md) | [59.9](/filings/0001193125-26-344636.md) |
| Operating income | $m | [(4.6)](/filings/0001558370-24-015524.md) | [(94.7) d](/filings/0001558370-25-003302.md) | [(132)](/filings/0001558370-25-007382.md) | [(40.0)](/filings/0000950170-25-104035.md) | [(50.5)](/filings/0001193125-25-269603.md) | [(83.0) d](/filings/0001193125-26-088172.md) | [(44.6)](/filings/0001193125-26-219425.md) | [(46.5)](/filings/0001193125-26-344636.md) | [(60.1)](/filings/0001193125-25-269603.md) | [(72.9) d](/filings/0001193125-26-088172.md) | [(59.3)](/filings/0001193125-26-219425.md) | [(78.1)](/filings/0001193125-26-344636.md) |
| Net income | $m | [(4.3)](/filings/0001558370-24-015524.md) | [(92.6) d](/filings/0001558370-25-003302.md) | [(129)](/filings/0001193125-25-269603.md) | [(36.1)](/filings/0001193125-25-269603.md) | [(47.1)](/filings/0001193125-25-269603.md) | [(80.2) d](/filings/0001193125-26-088172.md) | [(41.6)](/filings/0001193125-26-344636.md) | [(43.4)](/filings/0001193125-26-344636.md) | [(57.5)](/filings/0001193125-25-269603.md) | [(69.9) d](/filings/0001193125-26-088172.md) | [(53.8)](/filings/0001193125-26-344636.md) | [(73.1)](/filings/0001193125-26-344636.md) |
| Diluted EPS | $ per share | [(0.36)](/filings/0001558370-24-015524.md) | not reported | [(2.51)](/filings/0001558370-25-007382.md) | [(0.60)](/filings/0000950170-25-104035.md) | [(0.78)](/filings/0001193125-25-269603.md) | not reported | [(0.52)](/filings/0001193125-26-219425.md) | [(0.50)](/filings/0001193125-26-344636.md) | [(0.65)](/filings/0001193125-25-269603.md) | not reported | [(0.48)](/filings/0001193125-26-219425.md) | [(0.65)](/filings/0001193125-26-344636.md) |
| Basic EPS | $ per share | [(0.36)](/filings/0001558370-24-015524.md) | not reported | [(2.51)](/filings/0001558370-25-007382.md) | [(0.60)](/filings/0000950170-25-104035.md) | [(0.78)](/filings/0001193125-25-269603.md) | not reported | [(0.52)](/filings/0001193125-26-219425.md) | [(0.50)](/filings/0001193125-26-344636.md) | [(0.65)](/filings/0001193125-25-269603.md) | not reported | [(0.48)](/filings/0001193125-26-219425.md) | [(0.65)](/filings/0001193125-26-344636.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [90.6](/filings/0001558370-24-015524.md) | [98.7](/filings/0001558370-25-003302.md) | [270](/filings/0001558370-25-007382.md) | [165](/filings/0000950170-25-104035.md) | [156](/filings/0001193125-25-269603.md) | [143](/filings/0001193125-26-088172.md) | [258](/filings/0001193125-26-219425.md) | [144](/filings/0001193125-26-344636.md) | [273](/filings/0001193125-25-269603.md) | [653](/filings/0001193125-26-344636.md) | [583](/filings/0001193125-26-219425.md) | [218](/filings/0001193125-26-344636.md) |
| Current assets | $m | [91.4](/filings/0001558370-23-018425.md) | [145](/filings/0001558370-25-003302.md) | [313](/filings/0001558370-24-008066.md) | [284](/filings/0001558370-24-011898.md) | [244](/filings/0001558370-24-015524.md) | [221](/filings/0001193125-26-088172.md) | [323](/filings/0001558370-25-007382.md) | [277](/filings/0000950170-25-104035.md) | [280](/filings/0001193125-25-269603.md) | [661](/filings/0001193125-26-344636.md) | [594](/filings/0001193125-26-219425.md) | [538](/filings/0001193125-26-344636.md) |
| Total assets | $m | [93.2](/filings/0001558370-23-018425.md) | [149](/filings/0001558370-25-003302.md) | [320](/filings/0001558370-24-008066.md) | [296](/filings/0001558370-24-011898.md) | [257](/filings/0001558370-24-015524.md) | [240](/filings/0001193125-26-088172.md) | [343](/filings/0001558370-25-007382.md) | [296](/filings/0000950170-25-104035.md) | [299](/filings/0001193125-25-269603.md) | [683](/filings/0001193125-26-344636.md) | [620](/filings/0001193125-26-219425.md) | [565](/filings/0001193125-26-344636.md) |
| Current liabilities | $m | [23.1](/filings/0001558370-23-018425.md) | [21.8](/filings/0001558370-25-003302.md) | [30.8](/filings/0001558370-24-008066.md) | [39.9](/filings/0001558370-24-011898.md) | [39.5](/filings/0001558370-24-015524.md) | [54.3](/filings/0001193125-26-088172.md) | [30.8](/filings/0001558370-25-007382.md) | [22.9](/filings/0000950170-25-104035.md) | [31.4](/filings/0001193125-25-269603.md) | [45.0](/filings/0001193125-26-344636.md) | [27.4](/filings/0001193125-26-219425.md) | [35.7](/filings/0001193125-26-344636.md) |
| Total liabilities | $m | [87.1](/filings/0001558370-23-018425.md) | [28.7](/filings/0001558370-25-003302.md) | [34.2](/filings/0001558370-24-008066.md) | [42.4](/filings/0001558370-24-011898.md) | [42.0](/filings/0001558370-24-015524.md) | [59.1](/filings/0001193125-26-088172.md) | [35.6](/filings/0001558370-25-007382.md) | [27.0](/filings/0000950170-25-104035.md) | [35.5](/filings/0001193125-25-269603.md) | [48.8](/filings/0001193125-26-344636.md) | [31.1](/filings/0001193125-26-219425.md) | [40.3](/filings/0001193125-26-344636.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.1](/filings/0001558370-24-015524.md) | [120](/filings/0001193125-26-088172.md) | [286](/filings/0001193125-25-269603.md) | [254](/filings/0001193125-25-269603.md) | [215](/filings/0001193125-25-269603.md) | [181](/filings/0001193125-26-344636.md) | [307](/filings/0001193125-26-344636.md) | [269](/filings/0001193125-26-344636.md) | [264](/filings/0001193125-25-269603.md) | [634](/filings/0001193125-26-344636.md) | [589](/filings/0001193125-26-344636.md) | [525](/filings/0001193125-26-344636.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.6) d](/filings/0001558370-24-015524.md) | [(17.5) d](/filings/0001558370-25-003302.md) | [(11.2)](/filings/0001558370-25-007382.md) | [(23.4) d](/filings/0000950170-25-104035.md) | [(34.2) d](/filings/0001193125-25-269603.md) | [(42.1) d](/filings/0001193125-26-088172.md) | [(53.1)](/filings/0001193125-26-219425.md) | [(49.4) d](/filings/0001193125-26-344636.md) | [(40.5) d](/filings/0001193125-25-269603.md) | [(48.0) d](/filings/0001193125-26-088172.md) | [(58.6)](/filings/0001193125-26-219425.md) | [(61.7) d](/filings/0001193125-26-344636.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-015524.md) | [0.3 d](/filings/0001558370-25-003302.md) | [2.2](/filings/0001558370-25-007382.md) | [2.3 d](/filings/0000950170-25-104035.md) | [1.5 d](/filings/0001193125-25-269603.md) | [1.1 d](/filings/0001193125-26-088172.md) | [3.7](/filings/0001193125-26-219425.md) | [0.9 d](/filings/0001193125-26-344636.md) | [1.1 d](/filings/0001193125-25-269603.md) | [4.0 d](/filings/0001193125-26-088172.md) | [3.0](/filings/0001193125-26-219425.md) | [2.2 d](/filings/0001193125-26-344636.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.1](/filings/0001558370-23-018425.md) | [12.2](/filings/0001558370-24-008066.md) | [12.2](/filings/0001558370-24-011898.md) | [12.2](/filings/0001558370-24-015524.md) | [51.5](/filings/0001558370-25-007382.md) | [59.9](/filings/0000950170-25-104035.md) | [60.2](/filings/0001193125-25-269603.md) | [79.4](/filings/0001193125-26-219425.md) | [87.0](/filings/0001193125-26-344636.md) | [88.0](/filings/0001193125-25-269603.md) | [113](/filings/0001193125-26-219425.md) | [113](/filings/0001193125-26-344636.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 113,577,629 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344636.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.